Stroke researchers discuss finding silver linings in three recent neuroprotection studies
The Calgary Stroke Program, a joint University of Calgary and Alberta Health Services initiative at Foothills Medical Centre, ...
Business Wire19h
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Stopping Alzheimer’s Before It Starts: Landmark Trial Enrolls First Participants
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...
manilatimes4d
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company's FDA discussions confirmed that relapse-free survival ...
FierceBiotech5d
Conduit taps Charles River to build preclinical autoimmune case for AstraZeneca diabetes asset
Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...
manilatimes5d
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study ...